Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D473/00—Heterocyclic compounds containing purine ring systems
  • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
  • C07D473/36—Sulfur atom
  • C07D473/38—Sulfur atom attached in position 6

Definitions

• n is an integer from to 5 R is a member selected from the group consisting of:
• Y is a member selected from the group consisting of:
• alkyl having a straight or branched carbon chain of 1 to 5 atoms
• CH OH, -CH SH, -(CH )SCH and m in the last member being an integer from 1 to 3 and R being alkoxy having a straight or branched chain of 1 to 8 carbon atoms.
• the compounds have shown an antineoplastic effect in certain specific transplanta'ble mice tumors. They are distinguished by their high affinity to a particular organ or to the tissue of a particular organ and their acute and chronical toxicity is low.
• Various cancerostatic agents are known and have been used clinically. Such agents are 6-(4-carboxybutyl)-thio purine, 6-mercaptopurine, and S-fluorouracil. However, some of these agents are quite toxic and some have only limited specificity for particular organs. Also, their effective action in the body may be limited in time as shown by radioactive tracing methods.
• n is an integer from 0 to 5
• R is a member selected from the group consisting of:
• Y is a member selected from the group consisting of:
• alkyl having a straight or branched carbon chain of 1 to 5 atoms phenyl; --CH OH, -CH SH, (CH )SCH and (CH COR m in the last member being an integer from 1 to 3 and R being alkoxy having a straight or branched chain of 1 to 8 carbon atoms.
• the compounds of the invention have shown an antineoplastic effect in certain specific transplantable mice tumors.
• X is a chlorine atom or a N group.
• n and Y have the same meaning as in the Formula I, and R is alkoxy with a straight or branched carbon chain of 1 to 8 carbon atoms, to form a N-[6-(6- purinylthio)valeryl]amino acid ester of the Formula IV:
• n and Y have the same meaning as in Formula I and R has the same meaning as in Formula II.
• the resulting product is then saponified with alkali.
• it may be condensed once more, in succession, twice with an amino acid ester of the same type as shown in Formula III to form the corresponding ester either of the N-[-(6-purinylthio)valeryl]dipeptide, or of the N- [5- 6-purinylthio valeryl] tri peptide.
• the amino acid ester first obtained may be converted to the azide and may then be condensed with an amino acid ester of the general Formula III to form the corresponding ester of the dipeptide.
• the dipeptide may then be saponified by alkali to the free acid which latter thereupon is converted by another reaction with the amino acid ester in the presence of N,N-dicyclohexycarbodiimide to form the corresponding tripeptide ester.
• the condensation of the 6-(4-carboxylbutyl)thiopurine derivative of Formula II with an amino acid ester of Formula III is preferably carried out if X in Formula II is chlorine in a medium of an inert organic solvent such as a halogenated aliphatic hydrocarbon having from 1 to 2 carbon atoms, preferably methylene chloride by using either at least two equivalents of the amino acid ester or by using one equivalent of an organic tertiary base, such as triethylamine.
• an inert organic solvent such as a halogenated aliphatic hydrocarbon having from 1 to 2 carbon atoms, preferably methylene chloride
• the reaction is carried out in an inert organic solvent which may again be methylene chloride but may also be a solvent such as dimethylformamide or dioxane, using at least two equivalents of the amino acid ester or using again one equivalent of the ester with one equivalent of the organic base such as triethylamine.
• an inert organic solvent which may again be methylene chloride but may also be a solvent such as dimethylformamide or dioxane, using at least two equivalents of the amino acid ester or using again one equivalent of the ester with one equivalent of the organic base such as triethylamine.
• an aqueous alkali metal hydroxide solution e.g., of sodium or potassium hydroxide, in an amount of at least two equivalents in case of a monocarboxylic amino acid, and of at least three equivalents in case of a dicarboxylic amino acid ester.
• the reaction is carried out at a temperature of 025 C.
• reaction of the free N-[6-(6-purinylthio)valeryl] dipeptide acid with an amino acid ester of the Formula III, in the presence of N,N'-dicyclohexylcarbodiimide, to form the corresponding N-[6-(6-purinylthio)valeryl]tripeptide is preferably performed in the medium of an inert organic solvent, such as a halogenated aliphatic hydrocarbon having 12 carbon atoms, preferably methylene chloride.
• an inert organic solvent such as a halogenated aliphatic hydrocarbon having 12 carbon atoms, preferably methylene chloride.
• the derivative of 6-(4-carboxybutyl) thiopurine of Formula II e.g., the acid chloride which is used as the starting compound
• the condensation with the amino acid ester of Formula III can be carried out in the same medium without chloride isolation.
• Methylene chloride, as reaction medium is useful also here because in preparing derivatives of optically active amino acids with it, no racemization takes place.
• Another useful starting compound is the azide of 6-(4- carboxybutyl)thiopurine, which is easily available from the ester of the acid through the hydrazide thereof.
• the azide method is suitable also for the synthesis of N-[6- (6-purinylthio)valeryl]dipeptides, that is, by reaction of N-[5-(6-purinylthio)valeryl]amino acids (easily available from the corresponding hydrazides) with amino acid esters.
• the still slightly damp azide (6 g.) was placed into 30 ml. methylene chloride. To the suspension 16.1 g. (0.08 mole) of L-glutarnic acid diethyl ester were added and the mixture was left to stand for 2 days at laboratory temperatures. On extracting the reaction mixture by shaking with water (10 ml.) and with 1 M NaHCO and evaporation of the solvent in a water pump vacuum, the
• N-[6-(6-purinylthio)valeryl]glycine To a solution of 4.4 g. (0.11 mole) sodium hydroxide in 85 ml. water, 16.87 g. (0.05 mole) of N-[6-(6-purinylthio)valeryl]- glycine ethyl ester were added. After the material was dissolved the solution was left standing for 2 days at 20- 25 C. It then was acidified with dilute hydrochloric acid to pH 2-3, and the eliminated N-[6-(6-purinylthio) valeryl1glycine (15.1 g. 98%) was crystallized from water; M.P. 210-211.
• N-[6-(6-purinylthio)valeryl]-L-aspartic acid was was obtained by saponification of the N-[6-(6-purinylthio) valeryl]-L-aspartic acid diethyl ester (2.12 g., 5 mmole) with a solution of sodium hydroxide (0.66 g., 16 mmole) in water (21 ml.) at 0 to +5 (for 48 hours), or, alternatively, by the method of Example 6.
• the yield was 1.84 g. (100%) of N-[6-(purinylthio)valeryl]-L-aspartic acid; M.P. 198-199 (water), [u] +11".
• N [6 (6-purinylthio)valeryl]glycylglycine ethyl ester To a solution of 3.23 g. (0.01 mole) of N-[6- (6-purinylthio)valeryl]glycine hydrazide in 200 ml. of 0.1 M HCl, ml. of a 0.1 M NaNO- solution was added dropwise upon stirring at 0 to +5. Stirring was continued at that temperature until no more reaction with iodinestarch test paper occurred (about 1 hour). The suspension of the acid azide hydrochloride obtained was neutralized with 10 ml. of 1 M NaHCO 100 g.
• N-[6-(6-purinylthio)valeryl] glycine hydrazide used as starting product was prepared in the following manner: 3.5 g. of N-[6-(6-purinylthio)valeryl]glycine ethyl ester was placed upon stirring at 20 into 17.5 ml. hydrazine hydrate. The solution was left standing for 2 days at the laboratory temperature. After distilling off the excess hydrazine hydrate by water pump vacuum, the evaporation residue was stirred up with 7 ml.
• the compound formed colorless needles with a M.P. of 23 8-240.
• the N-[6-(6-purinylthio)va1eryl]glycylglycyl glycine, with a M.P. of 231-233 (water) was obtained.
• the following table illustrates the pharmaceutical action of some of the compounds of the invention.
• the table shows a composition with three well known cancerostatics, which are 6-(4-carboxybutyl) thiopurine, 6-mercaptopurine, and 5-fiuorouracil.
• mice H S180-Crocker sarcoma; SAK-the sarcoma originally induced by methylacridine; HK-milk gland adenocarcinoma; YYoshida ascitic reticulosarcoma of the Wister rat.
• the antineoplastic action is expressed as a fraction, the numerator of which indicates the average tumor size in a treated group of ten animals in percent of the average tumor size in an untreated, equally large control group (:100% When the comparison with the control group (100/100) shows differences greater than 20%, Fischers probability coefficient (in the arrangement applied) assumes values below 12:0.05.
• the substances tested were administered orally to mice at the optimum therapeutic doses established in 12 intervals during 24 hours, except that S-fluorouracil was applied subcutaneously. (In the table the doses in mg./kg. are quoted in parentheses.)
• the administration was started at the 3rd day after transplantation of the tumors S180, SAR, HK, and at the 2nd day for the Y growth.
• the tumor size was determined by weight after destruction of the animal.
• N-[5-(6-purinylthio)valeryl]glycylglycyl glycine (not listed in the table) has significant therapeutical action in mice H with the ascitic sarcoma S37 (64/123) (with the same manner of application, dosage and test arrangement as used in the evaluation of the comparable derivative of the diglycine ester).
• the analogous derivatives of glycine ethyl ester and diglycine ethyl ester were practically ineffective in case of the S37 tumor.
• the substances of the invention are at least equally or even more active in animals with a particular tumor than the 6-mercaptopurine and 5- fiuorouracil used for comparison.
• the feature of the amino acid or peptide, or ester thereof, as the case may be, which are attached to 6 (4 carboxybuty1)thiopurine by a peptidic bond, are effective in some instances and also quite significant in other parameters of the physiological action.
• the chronic toxicity of the basal substance 6-(4-carboxybutyl) thiopurine in mice LD about 12 g./kg. in oral application
• the analogous diglycine ethyl ester derivative is under the same conditions substantially less toxic. Its chronic toxicity expressed in LD exceeds 50 g./kg. in per os application.
• the radioactivity concentration decreases rapidly in both tissues within lapse of time,
• Y is hydrogen, lower alkyl, or (CH CO R'; m is 1 or 2; and R is H or lower alkyl.
• the compound of claim 1 which is N-[5-(6-purinylthio valeryl] -DL-isoleucine.
• Kaverzneva et al. Akad. Nauk SSSR., Izvestiia, Seriia Khimiia, 1966, 1l991203.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=5387083

Family Applications (1)

Country Status (12)

Cited By (2)

Families Citing this family (2)

• 1967
  • 1967-06-13 CH CH834867A patent/CH501652A/de not_active IP Right Cessation
  • 1967-06-14 GB GB27367/67A patent/GB1178329A/en not_active Expired
  • 1967-06-20 AT AT574367A patent/AT274000B/de active
  • 1967-06-23 DK DK327867AA patent/DK118136B/da unknown
  • 1967-06-26 SE SE02458/70A patent/SE353716B/xx unknown
  • 1967-06-26 US US649432A patent/US3567705A/en not_active Expired - Lifetime
  • 1967-06-26 SE SE02457/70A patent/SE353715B/xx unknown
  • 1967-06-26 SE SE09168/67*A patent/SE339473B/xx unknown
  • 1967-06-27 DE DE1695744A patent/DE1695744C3/de not_active Expired
  • 1967-06-28 YU YUP1301/67A patent/YU33829B/xx unknown
  • 1967-06-29 FI FI671814A patent/FI48737C/fi active
  • 1967-06-29 JP JP42042169A patent/JPS4832119B1/ja active Pending
  • 1967-06-30 BE BE700727D patent/BE700727A/xx unknown
  • 1967-06-30 NL NL676709151A patent/NL144615B/xx not_active IP Right Cessation

Also Published As

Similar Documents